Company Overview and News
In an effort to expand its business aviation dealer program, Viasat Inc. (VSAT - Free Report) recently announced the addition of two new installation partners to facilitate the increased use of its in-flight Internet solution. With the addition of GoAeroMx and SoCal Jets, Inc. as its installation partners, the number of authorized Viasat dealers extends to more than 20.
CBSH VSAT CMTL CBSHP UBNT SONS CBCB
Arista Networks, Inc. (ANET - Free Report) recently announced that Microsoft Azure Stack currently supports its Arista Any Cloud software platform. Notably, the platform includes the Arista vEOS router, which integrated with Arista CloudVision software offers safe networking operations and telemetry across several private and public cloud environments.
ANET PLT ACIA SONS
QUALCOMM Incorporated’s (QCOM - Free Report) subsidiary, Qualcomm Technologies, Inc. recently announced that it is offering Device Identification, Registration, and Blocking System (DIRBS) platform as an open source software. Notably, the DIRBS server-based software platform can be downloaded for free from the open-source software website, GitHub.
MDPEB VZ MDP QCOM SONS VZA
Viasat, Inc. (VSAT - Free Report) recently announced that its first ViaSat-3 payload module structure has been set at its Tempe, AZ facility. Henceforth, the company will commence its testing and payload integration activities for the first ViaSat-3 class satellite, which will likely start supplying more accessible and affordable broadband services across the Americas from 2020. The ViaSat-3 payload module structure has been constructed by The Boeing Company (BA - Free Report) .
VSAT BOE SCVL UBNT BA SONS PAYC
Nokia Corporation (NOK - Free Report) recently announced its licensing rate expectations for 5G mobile phones. The company said that it continues to innovate in 5G and remains optimistic about gaining a significant position in standard essential patents (SEPs), once the finalization of 5G standards is done later this year.
NOKIA NOK QCOM SONS CLFD
The earnings season is off to a solid start with decent performance across the table. About 87 S&P 500 members have already released their results till Apr 20. Total earnings for these companies are up 25% year over year on 10.7% higher revenues, with 82.8% beating earnings estimates and 67.8% surpassing top-line expectations. Based on the hitherto observed pattern, first-quarter 2018 is anticipated to register healthy double-digit percentage earnings growth on a year-over-year basis.
IDCC KN DVN VCRA SONS
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to SONS / Sonus Networks, Inc. on message board site Silicon Investor.
as of ET